These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase. Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301 [TBL] [Abstract][Full Text] [Related]
6. Comment on: Control of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae using a computer-assisted management program to restrict third-generation cephalosporin use. Huttner B; Pittet D; Harbarth S J Antimicrob Chemother; 2008 Nov; 62(5):1165; author reply 1165-6. PubMed ID: 18658195 [No Abstract] [Full Text] [Related]
8. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Labombardi VJ; Rojtman A; Tran K Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784 [TBL] [Abstract][Full Text] [Related]
9. Emergence of carbapenem resistance due to porin loss in an extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae strain during meropenem therapy. Webster DP; Gaulton T; Woodford N; Pike R; Turton J; Perry C; Bowler IC Int J Antimicrob Agents; 2010 Dec; 36(6):575-6. PubMed ID: 20869852 [No Abstract] [Full Text] [Related]
10. Transfer of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae from Turkey to France. Levast M; Poirel L; Carrër A; Deiber M; Decroisette E; Mallaval FO; Lecomte C; Nordmann P J Antimicrob Chemother; 2011 Apr; 66(4):944-5. PubMed ID: 21393135 [No Abstract] [Full Text] [Related]
11. Re: A VIM-1-metallo-beta-lactamase-producing Klebsiella pneumoniae clinical isolate in an acute hospital in Germany. Shah PM Int J Antimicrob Agents; 2009 Oct; 34(4):381. PubMed ID: 19502012 [No Abstract] [Full Text] [Related]
12. Klebsiellapneumoniae isolates possessing KPC beta-lactamase in Israel, Puerto Rico, Colombia and Greece. Hawser SP; Bouchillon SK; Hoban DJ; Hackel M; Johnson JL; Badal RE Int J Antimicrob Agents; 2009 Oct; 34(4):384-5. PubMed ID: 19560904 [No Abstract] [Full Text] [Related]
15. Extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Shanthi M; Sekar U J Assoc Physicians India; 2010 Dec; 58 Suppl():41-4. PubMed ID: 21568008 [TBL] [Abstract][Full Text] [Related]
16. Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae. Pai H; Seo MR; Choi TY Antimicrob Agents Chemother; 2007 Jan; 51(1):366-8. PubMed ID: 17074790 [TBL] [Abstract][Full Text] [Related]
19. Health and economic outcomes of the detection of Klebsiella pneumoniae-produced extended-spectrum beta-lactamase (ESBL) in a hospital with high prevalence of this infection. Marra AR; Pereira CA; Castelo A; do Carmo Filho JR; Cal RG; Sader HS; Wey SB Int J Infect Dis; 2006 Jan; 10(1):56-60. PubMed ID: 16326126 [TBL] [Abstract][Full Text] [Related]